Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > NMIBC Competitor's Pivotal Phase 3 Sustained Results

<< Previous

Bullboard Posts

Next >>

Comment by DJDawgon Sep 29, 2021 1:01pm

364 Views

Post# 33937425

RE:NMIBC Competitor's Pivotal Phase 3 Sustained Results

Thanks for sharing. This drug is a bit more complicated to make and would fall under a BLA, correct? That can makes things slower as have noticed that the production issues are more complex and the FDA seems more cautious about having detailed quality control data on the biologic agents.

<< Previous

Bullboard Posts

Next >>

Investors eye Australian gold mining projects amid promising developments